ABVC Biopharma Files Amendment to S-1 Registration Statement

TL;DR

<b>ABVC Biopharma is amending its S-1 registration statement, indicating ongoing efforts to offer securities.</b>

AI Summary

ABVC BIOPHARMA, INC. (ABVC) filed a Amended IPO Registration (S-1/A) with the SEC on February 16, 2024. ABVC Biopharma, Inc. filed an S-1/A (Amendment No. 2) with the SEC on February 16, 2024. The filing pertains to a registration statement under the Securities Act of 1933. The company's principal executive offices are located at 44370 Old Warm Springs Blvd., Fremont, CA 94538. Dr. Uttam Patil is listed as the Chief Executive Officer. The filing indicates the proposed sale of securities may commence as soon as practicable after the registration statement is declared effective.

Why It Matters

For investors and stakeholders tracking ABVC BIOPHARMA, INC., this filing contains several important signals. This amendment suggests ABVC Biopharma is actively working towards a public offering of its securities, which could provide capital for operations and growth. The S-1 filing is a crucial step for companies looking to raise funds through the stock market, and amendments often signal progress in the process.

Risk Assessment

Risk Level: — ABVC BIOPHARMA, INC. shows moderate risk based on this filing. The filing is an amendment to a registration statement, not a report of financial performance or significant operational changes, thus posing minimal immediate risk.

Analyst Insight

Monitor future filings for updates on the effectiveness of the registration statement and details of any subsequent securities offering.

Executive Compensation

Key Players & Entities

• ABVC BIOPHARMA, INC. (company) — Filer name
• 2024-02-16 (date) — Filing date
• S-1/A (document) — Filing type
• 333-276500 (registration_number) — Registration number
• 44370 Old Warm Springs Blvd., Fremont, CA 94538 (address) — Principal executive offices
• Dr. Uttam Patil (person) — Chief Executive Officer
• Nevada (jurisdiction) — State of incorporation
• 1933 Act (regulation) — Securities Act

FAQ

Industry Context

ABVC Biopharma operates in the pharmaceutical preparations industry, focusing on the development and commercialization of biopharmaceutical products.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration and regulation of securities offered to the public in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the proposed securities offering.
2. Track the SEC's review process and any further amendments to the registration statement.
3. Analyze ABVC Biopharma's business strategy and financial health in conjunction with this filing.

Year-Over-Year Comparison

This is an amendment to a previous S-1 filing, indicating ongoing regulatory processes rather than a new filing event.

Key Financial Figures

• $0.001 — , a Nevada corporation (the "Company"), $0.001 par value (the "Common Stock"). These s
• $1.26 — e closing price of our common stock was $1.26 per share. The Selling Stockholders m
• $1,200,000 — LP ("Lind") in the principal amount of $1,200,000 (the "2 nd Lind Note"), at a conversion
• $3.50 — price, which shall be the lesser of (i) $3.50 (the "Fixed Price") and (ii) 90% of the
• $2 — rrant") at an initial exercise price of $2 per share, (c) 30,000 shares of Common
• $0.0001 — 00,000,000 shares authorized, par value $0.0001. Its key Subsidiaries include BioLite B
• $6.30 — mon stock at an exercise price equal to $6.30 per share, exercisable until the fifth
• $10.00 — mon stock at an exercise price equal to $10.00 per share, exercisable until the fifth
• $6.25 — n Statement"). The Units were priced at $6.25 per Unit, before underwriting discounts
• $6,875,000 — xpenses, resulting in gross proceeds of $6,875,000. The Offering was conducted on a firm c
• $1.00 — our common stock was below the minimum $1.00 per share required for continued listin
• $2,500,000 — intain stockholders' equity of at least $2,500,000, and the Company's stockholders' equity
• $1,734,507 — the Company's stockholders' equity was $1,734,507 as of March 31, 2023. In accordance wit

Filing Documents

• ea193878-s1a2_abvcbio.htm (S-1/A) — 2963KB
• image_001.jpg (GRAPHIC) — 18KB
• image_002.jpg (GRAPHIC) — 18KB
• image_003.jpg (GRAPHIC) — 22KB
• image_004.jpg (GRAPHIC) — 4KB
• image_005.jpg (GRAPHIC) — 12KB
• 0001213900-24-014947.txt (&nbsp;) — 13006KB
• abvc-20230930.xsd (EX-101.SCH) — 127KB
• abvc-20230930_cal.xml (EX-101.CAL) — 53KB
• abvc-20230930_def.xml (EX-101.DEF) — 554KB
• abvc-20230930_lab.xml (EX-101.LAB) — 882KB
• abvc-20230930_pre.xml (EX-101.PRE) — 571KB
• ea193878-s1a2_abvcbio_htm.xml (XML) — 1697KB

RISK FACTORS

RISK FACTORS 8 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 27

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 29

BUSINESS

BUSINESS 61 MANAGEMENT 76

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 81

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 85 RELATED PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS OF THE COMBINED COMPANY 86

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 90 SELLING STOCKHOLDERS 92 PLAN OF DISTRIBUTION 93 LEGAL MATTERS 9 5 EXPERTS 9 5 WHERE YOU CAN FIND MORE INFORMATION 9 5 You should rely only on the information contained in this prospectus or in any free writing prospectus that we may specifically authorize to be delivered or made available to you. We and our Underwriter have not authorized anyone to provide you with any information other than that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus may only be used where it is legal to offer and sell our securities. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of these securities in any jurisdiction where the offer is not permitted. Unless the context otherwise requires, the terms "ABVC," "we," "us" and "our" in this prospectus refer to ABVC BIOPHARMA, INC., and "this offering" refers to the offering contemplated in this prospectus. i PROSPECTUS CONVENTIONS Except where the context otherwise requires and for purposes of this prospectus only: "American BriVision Corporation" refers to a Delaware corporation and wholly-owned subsidiary of ABVC; "APR" or "annual percentage rate" refers to the annual rate that is charged to borrowers, including a fixed interest rate and a transaction fee rate, expressed as a single percentage number that represents the actual yearly cost of borrowing over the life of a loan; "BioKey" means BioKey, Inc. refers to a California corporation and wholly-owned subsidiary of ABVC; "BioLite" means BioLite Holding, Inc. re

View Full Filing

View this S-1/A filing on SEC EDGAR